Main Media English

Get Latest News, India News, World News at Main Media English

Support Us

UK approves non-hormonal menopause drug to prevent hot flashes

IANS logo Reported By IANS |
Published On :

London, Dec 18 (IANS) Health authorities in the UK have approved a menopause drug that can prevent hot flashes, and help scores of women for whom hormone replacement therapy is not suitable.

The once daily prescription-only medicine, known as Veozatm (fezolinetant) 45 mg can aid in the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.

Also Read Story

Empty chairs, forced attendance allegations cast shadow on INDIA bloc’s Delhi rally

Nagaland’s sole LS seat to witness triangular contest in 2024 polls

Odisha Crime Branch busts racket involved in Rs 1.04 cr fraud

IPL 2024: Under-pressure Mumbai Indians hope to shine in home comfort (Preview)

IPL 2024: Sai Sudharsan, David Miller star as clinical Gujarat beat Hyderabad by seven wickets

Viksit Bharat Ambassador meet-up: India is world’s 3rd largest start-up ecosystem today, says I&B Minister Anurag Thakur

Amit Shah chairs meeting of Lok Sabha core committees in Jaipur, holds roadshow in Sikar

IPL 2024: Ishant Sharma back as Delhi Capitals win toss, elect to bat against CSK

Viksit Bharat Ambassador Jaipur meet-up: Participants heap praise on the initiative

VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause. Worldwide, more than half of women 40 to 64 years of age experience. VMS can have a disruptive impact on women’s daily activities and overall quality of life.


Veoza is a nonhormonal drug that directly acts on the brain to prevent hot flashes. It works by blocking neurokinin B (NKB) binding on the kisspeptin/neurokinin/dynorphin (KNDy) neuron to modulate neuronal activity in the brain’s temperature control center (the hypothalamus) to reduce the number and intensity of hot flashes and night sweats.

“Hot flushes and night sweats caused by menopause are common, and can have a significant impact on a woman’s daily life. We are therefore pleased to have authorised Veoza (fezolinetant) for hot flushes and night sweats caused by menopause via our reliance procedure,” Julian Beach, the interim executive director of healthcare quality and access at the Medicines and Healthcare Products Regulatory Agency (MHRA), was quoted as saying to the Guardian.

“No medicine would be approved unless it met our expected standards of safety, quality and effectiveness, and we continue to keep the safety of all medicines under close review,” he added.

Veoza has been approved for use in women experiencing hot flushes associated with the menopause with immediate effect. However, it has not been studied for safety and efficacy in women over the age of 65, the MHRA said, so no dose recommendation can yet be made for this age group.

–IANS

rvt/vd

(This report is auto-generated from IANS news service. 'Main Media' holds no responsibility for its content.)

Get involved in bringing the ground realities of Seemanchal. Click the "Support Us" button to join our membership.

Support Us

Related News

Pawar vs Pawar: A fight for supremacy in Baramati

Rebel Wilson opens up on weight loss journey, says she’s an emotional eater

Shraddha Kapoor asks fans how they wasted 1st quarter of 2024

PM Modi virtually interacts with party workers in Varanasi

AIADMK will ally again with BJP after LS elections, says Chidambaram

PE-VC investments fall by 8 per cent to $6.2 billion in Q1

Cut! Mark Ronson’s role in Amy Winehouse biopic gets axed

Leave a Reply

Your email address will not be published. Required fields are marked *